Literature DB >> 26366427

Measuring Outcome in the Treatment of Cocaine Dependence.

Paul Crits-Christoph1, Robert Gallop2, Mary Beth Connolly Gibbons1, Jaclyn S Sadicario1, George Woody1.   

Abstract

BACKGROUND: Little in known about the extent to which outcome measures used in studies of the treatment of cocaine dependence are associated with longer-term use and with broader measures of clinical improvement. The current study examined reductions in use, and abstinence-oriented measures, in relation to functioning and longer-term clinical benefits in the treatment of cocaine dependence.
METHODS: Overall drug use, cocaine use, and functioning in a number of addiction-related domains for 487 patients diagnosed with DSM-IV cocaine dependence and treated with one of four psychosocial interventions in the NIDA Cocaine Collaborative Treatment Study were assessed monthly during 6 months of treatment and at 9, 12, 15, and 18 month follow-up.
RESULTS: Measures of during-treatment reduction in use were moderately correlated with drug and cocaine use measures 12 months, but showed non-significant or small correlations with measures of functioning at 12 months. Highest correlations were evident for abstinence measures (maximum consecutive days abstinence and completely abstinent) during treatment in relation to sustained (3 month) abstinence at 12 months. Latent class analysis of patterns of change over time revealed that most patients initially (months 1 to 4 of treatment) either became abstinent immediately or continued to use every month. Over the couse of follow-up, patients either maintained abstinence or used regularly - intermittent use was less common.
CONCLUSIONS: There were generally small associations between various measures of cocaine use and longer-term clinical benefits, other than abstinence was associated with continued abstinence. No one method of measuring outcome of treatment of cocaine dependence appears superior to others.

Entities:  

Keywords:  Abstinence; Cocaine Dependence; Patterns of Change; Psychosocial Treatment; Relapse

Year:  2013        PMID: 26366427      PMCID: PMC4564116          DOI: 10.4172/2329-6488.1000108

Source DB:  PubMed          Journal:  J Alcohol Drug Depend        ISSN: 2329-6488


  43 in total

1.  A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial.

Authors:  David J McCann; Shou-Hua Li
Journal:  CNS Neurosci Ther       Date:  2011-10-18       Impact factor: 5.243

2.  Natural classes of treatment response.

Authors:  A R Morral; M Y Iguchi; M A Belding; R J Lamb
Journal:  J Consult Clin Psychol       Date:  1997-08

3.  Psychosocial treatments for cocaine abuse. 12-month treatment outcomes.

Authors:  J A Hoffman; B D Caudill; J J Koman; J W Luckey; P M Flynn; D W Mayo
Journal:  J Subst Abuse Treat       Date:  1996 Jan-Feb

4.  A controlled trial of fluoxetine in crack cocaine dependence.

Authors:  S L Batki; A M Washburn; K Delucchi; R T Jones
Journal:  Drug Alcohol Depend       Date:  1996-06       Impact factor: 4.492

5.  Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets.

Authors:  Joy M Schmitz; Jan A Lindsay; Angela L Stotts; Charles E Green; F Gerard Moeller
Journal:  Exp Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.157

6.  Drug poisoning deaths in the United States, 1980-2008.

Authors:  Margaret Warner; Li Hui Chen; Diane M Makuc; Robert N Anderson; Arialdi M Miniño
Journal:  NCHS Data Brief       Date:  2011-12

7.  Nefazodone treatment of cocaine dependence with comorbid depressive symptoms.

Authors:  Domenic A Ciraulo; Clifford Knapp; John Rotrosen; Ofra Sarid-Segal; Ann Marie Ciraulo; Joseph LoCastro; David J Greenblatt; Deborah Leiderman
Journal:  Addiction       Date:  2005-03       Impact factor: 6.526

8.  Cocaine use trajectories of club drug-using young adults recruited using time-space sampling.

Authors:  Danielle E Ramo; Christian Grov; Kevin L Delucchi; Brian C Kelly; Jeffrey T Parsons
Journal:  Addict Behav       Date:  2011-08-24       Impact factor: 3.913

9.  Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial.

Authors:  David McDowell; Edward V Nunes; Angela M Seracini; Jami Rothenberg; Suzanne K Vosburg; Guoguang J Ma; Eva Petkova
Journal:  Drug Alcohol Depend       Date:  2005-11-01       Impact factor: 4.492

10.  Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial.

Authors:  F Gerard Moeller; Joy M Schmitz; Joel L Steinberg; Charles M Green; Christopher Reist; Lingo Y Lai; Alan C Swann; John Grabowski
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

View more
  6 in total

1.  Statistical considerations in the choice of endpoint for drug use disorder trials.

Authors:  Garrett M Fitzmaurice; Stuart R Lipsitz; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2017-10-18       Impact factor: 4.492

2.  Changes in health outcomes as a function of abstinence and reduction in illicit psychoactive drug use: a prospective study in primary care.

Authors:  Tae Woo Park; Debbie M Cheng; Christine A Lloyd-Travaglini; Judith Bernstein; Tibor P Palfai; Richard Saitz
Journal:  Addiction       Date:  2015-09       Impact factor: 6.526

3.  Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial.

Authors:  Joy M Schmitz; Scott D Lane; Michael F Weaver; Ponnada A Narayana; Khader M Hasan; DeLisa D Russell; Robert Suchting; Charles E Green
Journal:  Contemp Clin Trials       Date:  2021-10-22       Impact factor: 2.226

Review 4.  Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.

Authors:  Brian D Kiluk; Kathleen M Carroll; Amy Duhig; Daniel E Falk; Kyle Kampman; Shengan Lai; Raye Z Litten; David J McCann; Ivan D Montoya; Kenzie L Preston; Phil Skolnick; Constance Weisner; George Woody; Redonna Chandler; Michael J Detke; Kelly Dunn; Robert H Dworkin; Joanne Fertig; Jennifer Gewandter; F Gerard Moeller; Tatiana Ramey; Megan Ryan; Kenneth Silverman; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2015-11-21       Impact factor: 4.492

5.  A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.

Authors:  Joy M Schmitz; Charles E Green; Angela L Stotts; Jan A Lindsay; Nuvan S Rathnayaka; John Grabowski; F Gerard Moeller
Journal:  Drug Alcohol Depend       Date:  2014-01-03       Impact factor: 4.492

6.  Within-treatment frequency of use versus abstinence as a predictor of longitudinal post-treatment follow-up assessments of drug use.

Authors:  Garrett M Fitzmaurice; Stuart R Lipsitz; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2020-01-17       Impact factor: 4.492

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.